CNBX Stock Chart & Stats
<$0.01
<$0.01(9900.00%)
At close: 4:00 PM EDT
<$0.01
<$0.01(9900.00%)
Day’s Range― - ―
52-Week Range<$0.01 - $0.02
Previous CloseN/A
Volume5.81M
Average Volume (3M)70.56K
Market Cap
$160.58K
Enterprise Value$76.72K
Total Cash (Recent Filing)$9.49K
Total Debt (Recent Filing)$120.00K
Price to Earnings (P/E)0.1
Beta14.67
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding1,605,768,100
10 Day Avg. Volume49,020
30 Day Avg. Volume70,560
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.02
Price to Sales (P/S)0.00
P/FCF Ratio-0.26
Enterprise Value/Market Cap0.48
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.18
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
CNBX Pharmaceuticals News
CNBX FAQ
What was CNBX Pharmaceuticals’s price range in the past 12 months?
CNBX Pharmaceuticals lowest stock price was <$0.01 and its highest was $0.01 in the past 12 months.
What is CNBX Pharmaceuticals’s market cap?
CNBX Pharmaceuticals’s market cap is $160.58K.
When is CNBX Pharmaceuticals’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were CNBX Pharmaceuticals’s earnings last quarter?
Currently, no data Available
Is CNBX Pharmaceuticals overvalued?
According to Wall Street analysts CNBX Pharmaceuticals’s price is currently Overvalued.
Does CNBX Pharmaceuticals pay dividends?
CNBX Pharmaceuticals does not currently pay dividends.
What is CNBX Pharmaceuticals’s EPS estimate?
CNBX Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CNBX Pharmaceuticals have?
CNBX Pharmaceuticals has 1,605,768,100 shares outstanding.
What happened to CNBX Pharmaceuticals’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of CNBX Pharmaceuticals?
Currently, no hedge funds are holding shares in CNBX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
CNBX Pharmaceuticals
CNBX Pharmaceuticals Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing cannabinoid-based treatments and therapies for various cancers. Its flagship product candidate, RCC-33, is an oral capsule formulation of cannabinoids specifically engineered for treating colorectal cancer. The company's development pipeline also encompasses several other potential drug candidates, including PLP-33, which targets lateral spreading or sessile colorectal polyps during colonoscopy; BRST-33, aimed at breast cancer; MLN-33, designed for melanoma; and PRST-33, intended for prostate cancer. Furthermore, CNBX is developing Cannabics SR, a lipid-based capsule containing a standardized blend of cannabinoids for managing cancer anorexia-cachexia syndrome, alongside Cannabics CDx, an ex-vivo drug sensitivity diagnostic tool. Incorporated in 2004, the company, based in Bethesda, Maryland, was formerly known as Cannabics Pharmaceuticals Inc. before officially changing its name in March 2022. It operates as a subsidiary of Cannabics Inc.
InMed Pharmaceuticals
―
PharmaCyte Biotech
―
CNS Pharmaceuticals
―
GRI Bio
―
SciSparc Ltd.
―